High-Dose IV Immunoglobulin in Juvenile Myasthenia

Abstract

Ten children (median age, 13 years; range, 3-18 yrs) with juvenile myasthenia gravis were treated with high-dose intravenous immunoglobulin (2 gm/kg body wt) and prospectively evaluated for 5 years at the Department of Neurology, Wayne State University, Children’s Hospital of Michigan, Detroit, MI.

Keywords

• high-dose iv immunoglobulin
• juvenile myasthenia
• myasthenic crisis